RecallReported November 4, 2026

Class II recall by Brandywine Pharmaceuticals, LLC

Theophylline Extended-Release Tablets, 200 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA …

FDA's record ↗

FDA's enforcement report of November 4, 2026 lists a Class II recall by Brandywine Pharmaceuticals, LLC of West Chester, PA. Product: Theophylline Extended-Release Tablets, 200 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA …. Status: Ongoing.

On the record

Recalling firm
Brandywine Pharmaceuticals, LLC
Location
West Chester, PA
Classification
Class II
Status
Ongoing
Recall number
D-0111-2027
Product type
Drugs
Recall initiated
2026-10-06
Reported by FDA
2026-11-04
Source
FDA enforcement reports ↗

The full record

An account shows the reason for the recall, where the product was distributed and the lots.

What a recall is

FDA classifies a recall by the hazard. Class I: a reasonable probability that the product will cause serious adverse health consequences or death. Class II: the product may cause temporary or medically reversible harm, or the probability of serious harm is remote. Class III: the product is not likely to cause adverse health consequences.

More

Watch Brandywine Pharmaceuticals, LLC

A free account shows the last 7 days of every record. Pro adds a watchlist: one email when FDA acts on a company you name.

From FDA enforcement reports. The record may have changed since it was read.

Approve Suite is not affiliated with FDA, or with Brandywine Pharmaceuticals, LLC.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.